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ABSTRACT
The transcription factors Gli2 (glioma-associated
factor 2), which is a transactivator of Sonic
Hedgehog (Shh) signalling, and myocyte enhancer
factor 2C (MEF2C) play important roles in the devel-
opment of embryonic heart muscle and enhance
cardiomyogenesis in stem cells. Although the
physiological importance of Shh signalling and
MEF2 factors in heart development is well known,
the mechanistic understanding of their roles is
unclear. Here, we demonstrate that Gli2 and
MEF2C activated each other’s expression while
enhancing cardiomyogenesis in differentiating
P19 EC cells. Furthermore, dominant-negative
mutant proteins of either Gli2 or MEF2C re-
pressed each other’s expression, while impairing
cardiomyogenesis in P19 EC cells. In addition, chro-
matin immunoprecipitation (ChIP) revealed associ-
ation of Gli2 to the Mef2c gene, and of MEF2C to
the Gli2 gene in differentiating P19 cells. Finally,
co-immunoprecipitation studies showed that Gli2
and MEF2C proteins formed a complex, capable of
synergizing on cardiomyogenesis-related pro-
moters containing both Gli- and MEF2-binding
elements. We propose a model whereby Gli2 and
MEF2C bind each other’s regulatory elements,
activate each other’s expression and form a
protein complex that synergistically activates tran-
scription, enhancing cardiac muscle development.
This model links Shh signalling to MEF2C function
during cardiomyogenesis and offers mechanistic
insight into their in vivo functions.
INTRODUCTION
The mammalian heart is the ﬁrst organ to develop and is
essential for life. Perturbations in cardiogenesis can lead to
congenital heart disease, the most prevalent birth defect
worldwide. Heart development in vivo starts with the for-
mation of the cardiac crescent, where the ﬁrst heart ﬁeld
progenitor cells fuse to form the linear heart tube and give
rise to the left ventricle. Second heart ﬁeld progenitor
cells then migrate to form pharyngeal and splanchnic
mesoderm, which will form the right ventricle and the
outﬂow tract (1,2). In order to properly deﬁne and
maintain the cardiac identity, Sonic Hedgehog (Shh)
signalling pathway members and myocyte enhancer
factor 2 (MEF2) proteins are required as shown by
various animal models [(3–10) and reviewed in ref. (1,2)].
In mammals, the Shh signal is transmitted into the cell
by the patched1/smoothened (Ptch1/Smo) regulatory
complex and is mediated by transcription factors
glioma-associated factor (Gli) 1, 2, 3 [reviewed in refs
(11,12)], which bind the TGGGTGGTC DNA consensus
sequence (13). Gli1 acts as a transcriptional activator,
but is dependent on Gli2- and/or Gli3-mediated transcrip-
tion. Gli2 is a primary mediator of Shh signalling and
functions mainly as a transcriptional activator. Gli3 is
a transcriptional repressor (11). Using genetic inducible
fate mapping, members of the Shh signalling pathway
were shown to be expressed in murine myocardial progeni-
tor cells starting from embryonic day (E) 7.0–8.0 (3).
The expression of Gli1 in some atrial and ventricular
myocytes was conﬁrmed in another study when tamoxi-
fen was administered to the R26R
Gli1-CreERT2 embryos
at E6.5 (10). Thus, embryonic cardiomyocytes and/or
cardiac progenitors were exposed to Shh signalling
during development.
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proper number of cardiac progenitor cells during early
vertebrate heart development in zebraﬁsh (3). Inhibition
of the Shh signalling resulted in an early defect in myocar-
dial progenitor speciﬁcation leading to reduction of both
ventricular and atrial cardiomyocytes (3). Additionally,
activation of Shh signalling resulted in an increase of
cardiomyocytes (3). The importance of the Shh signalling
pathway in mammalian heart development was demon-
strated by total and tissue-speciﬁc knockout studies.
Smo
 /  mice showed delayed formation of heart tube
with delayed Nkx2-5 expression (4), whereas Ptch1
 / 
mice, where the negative regulation of Shh signalling
was removed, demonstrated upregulated Nkx2-5 expres-
sion during heart development (4). Moreover, in Shh
 / 
mice there were atrial septal defects and aberrant develop-
ment of the outﬂow tract (5). Additionally, Gli2
 / Gli3
+/
  mice showed cardiac outﬂow tract anomalies (6,14).
Tissue-speciﬁc removal of the Shh signalling pathway
members in murine second heart ﬁeld demonstrated their
role in atrioventricular septation and the development of
the outﬂow tract (8–10). In addition, Shh signalling was
found to be important in proliferation of second heart
ﬁeld progenitors in chicken embryos (7). Therefore, Shh
signalling via Gli2 is important for embryonic heart
development.
In addition to Gli transcription factors, cardio-
myogenesis is also regulated by MEF2 family members.
The four vertebrate MEF2 proteins, MEF2A, MEF2B,
MEF2C and MEF2D belong to the MADS box family
(MCM1, Agamous, Deﬁciens, SRF) of transcription
factors and bind A/T rich DNA sequence (T/C)TA(A/
T)4TA(G/A) (15). MEF2C is the ﬁrst MEF2 family
factor to be expressed in heart myocardium progenitors
starting from E7.5 (16,17).
Loss-of-function mutations in the single Mef2 gene in
Drosophila lead to a block of the development of all
muscle cell types during embryogenesis (18). In mamma-
lian embryogenesis, however, the four MEF2 family
members play redundant roles and can rescue the pheno-
type resulting from a speciﬁc Mef2 gene knockout
[reviewed in ref. (15)]. For example, Mef2c-null mice
undergo cardiomyogenesis but die from a failure to
undergo heart looping morphogenesis and proper devel-
opment of the right ventricle, as well as the outﬂow tract
(19,20). Cardiomyogenesis might be occurring due to a
7-fold increase in MEF2B protein observed in Mef2c-
null mice, which can partially compensate for the pheno-
type. Overlapping functions of MEF2C and MEF2B are
also supported by the evidence of normal development of
Mef2b-null mice (19). The possibility of the phenotype
rescue by other MEF2 family members was eliminated
by expression of a dominant-negative fusion protein, of
MEF2C with the engrailed repression (EnR) domain
(MEF2C/EnR) under the control of the Nkx2-5
enhancer that resulted in a severe disruption of cardio-
myogenesis in mice (21). Thus, both Shh signalling and
MEF2 family proteins play an important role in
cardiomyogenesis in vivo.
The results from in vivo experiments have largely been
reproduced in vitro. First, members of the Hedgehog
signalling pathway and MEF2 transcription factors are
expressed during cardiomyogenesis in embryonic stem
(ES) cells (22–25). During cardiomyogenesis in mouse
ES (mES) cells, committed cardiac progenitor cells
express MEF2C and GATA-4 transcription factors after
the formation of the mesodermal cells as characterized by
the expression of Brachyury T (BraT) and Oct-4. Cardiac
progenitor cells terminally differentiate into
cardiomyocytes and express contractile proteins such as
myosin heavy chain (MHC) and cardiac Troponin T (22).
A similar pattern of gene expression to ES cells can be
seen in studies using pluripotent P19 embryonal carcin-
oma (EC) cells (26–28). The P19 EC cells were originally
isolated from an induced teratocarcinoma of male mouse
testes by injection of isolated mES cells (26). These cells
can contribute to tissues in live-born chimeric mice (29)
and can undergo controlled differentiation into cardiac
and skeletal muscle cells (up to 15%) in vitro when
treated with dimethylsulphoxide (DMSO) (27,28,30–34).
We have previously shown that retinoic acid regulates
skeletal myogenesis in P19 EC, mouse and human ES
cells through upregulation of Pax3/7-positive progenitor
cells (35,36), similar to a role for retinoic acid and Pax3/7
progenitors during embryogenesis (37,38). Moreover,
Nkx-MEF2C/EnR was found to abrogate cardiac
myogenesis both during murine embryogenesis and in
P19 EC cells (21). Similarly, Nkx/EnR impaired cardiac
muscle formation in vivo (39) and in P19 EC cells (40).
More recently, we found that skeletal myosin light chain
kinase (MLCK) is important for skeletal myogenesis in
mES and P19 EC cells, as well as in the activation of sat-
ellite cells via interaction and subsequent phosphorylation
of the MEF2C protein (25). For Gli2 and MEF2C expres-
sion, previous publications demonstrate that the members
of the Shh signalling pathway and MEF2 family mem-
bers are expressed during cardiomyogenesis in P19 EC
cells (41,42) and P19CL6 cells (43,44), as well as in
cardiomyocytes derived from mES cells stably expressing
the neomycin-resistance gene under the regulation of the
cardiac a-MHC promoter (23). Therefore, P19 EC cells
use similar pathways as those identiﬁed in the embryo,
mouse and human ES cells and are a suitable model to
study cardiac and skeletal myogenesis in vitro.
Gain-of-function experiments in P19 EC cells revealed
that both Gli2 and MEF2C are able to induce
cardiomyogenesis through the upregulation of Nkx2-5,
GATA-4 and BMP-4 factors (41,45). Inhibition of Shh
signalling in vitro resulted in aberrant cardiomyogenesis
in P19 and P19CL6 cells (42,43). Surprisingly, the ubiqui-
tous expression of MEF2C/EnR, driven by the pgk
promoter, enhanced cardiomyogenesis in P19 cells, likely
by binding and inhibiting Class II histone deacetylases
(HDACs), resulting in the recruitment of non-cardiac
muscle cells into the lineage (46). However, consistent
with the gain-of-function experiments, the cardiac-
restricted expression of MEF2C/EnR, driven by an
Nkx2-5 enhancer, ablated cardiomyogenesis in P19 EC
cells (21), demonstrating that MEF2 factors, or genes
regulated by MEF2, are essential for cardiomyogenesis.
Therefore, Shh signalling members and MEF2 proteins
are important for cardiomyogenesis in stem cells.
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tiation programs in a similar fashion (41,45,47,48), and
their physiological role in heart development is known
[(3–6,18,21) and reviewed in ref. (15)], their detailed
function and the mechanism of their regulation is
unclear. In this article, we examined the relationship
between Gli2 and MEF2C during mES and P19 EC
cellular cardiomyogenesis. We have found that Gli2 and
MEF2C regulate each other’s expression and associate
with their respective gene elements, as well as form a
protein complex capable of synergizing on gene pro-
moters. We therefore link, for the ﬁrst time, the Sonic
Hedgehog signalling pathway to the function of MEF2C
protein during cardiomyogenesis in vitro.
METHODS
Transgenic mice
Gli2
+/  heterozygous mice [obtained from Dr A. Joyner,
Sloan-Kettering Institute, New York, NY, USA; (49)]
were maintained on CD1 background. Gli2
 /  homozy-
gous mice were generated by crossing two Gli2
+/  hetero-
zygous mice.
mES cell culture
D3 mES cells (ATCC, # CRL-1934) were maintained as
described in ref. (25,35). For differentiation, cells were
aggregated in hanging drops containing 800 cells each
for the ﬁrst 2 days. After culturing aggregates in suspen-
sion for an additional 5 days, they were plated on
tissue-culture grade adherent plates or 0.1%-gelatin
covered coverslips for the remaining 2 days of the 9-day
differentiation protocol.
P19 EC cell culture
P19 EC cells (ATCC, #CRL-1825) were cultured and
differentiated in the presence of 1% DMSO as previously
described (50). Brieﬂy, cells were aggregated in the
presence of DMSO for 4 days and formed aggregates
were plated onto 0.1%-gelatin covered coverslips or
adherent tissue-culture grade dishes. P19 EC cells
overexpressing various factors including P19[Gli2],
P19[MEF2C], P19[Control], P19[Gli/EnR], P19[MEF2C-
TAP] and P19[TAP] cells were described elsewhere (25,47).
P19[Nkx-MEF2C/EnR] cells stably overexpressing
MEF2C/EnR under the regulation of the Nkx2-5
enhancer (within the region from  9435 to  7353nt
relative to Nkx2-5 transcriptional start site) were
described in ref. (21).
Immunoﬂuorescence
On Day 6 of P19 EC and Day 9 of mES cell differenti-
ation, cultures were ﬁxed and incubated with MF20 mono-
clonal antibody supernatant to detect expression of MHC
as previously described (50). Cy3-conjugated secondary
antibodies (Jackson Immuno Research Laboratories,
USA) were used to detect immunoﬂuorescence (IF) as
described in ref. (51). Hoechst dye was used as a nuclear
marker. Indirect IF was captured using a Leica
DMI6000B microscope (Leica Microsystems GmbH,
Germany) or a Zeiss Axioscope microscope (Carl Zeiss
MicroImaging GmbH, Germany). Images were collected
at  200 or  400 magniﬁcation using Hamamatsu Orca
AG camera (Hamamatsu Photonics, Germany) or Sony
3CCD camera (Sony Corporation, Japan) and processed
using Velocity 4.3.2 (Perkin Elmer, Canada) or Axiovision
(Carl Zeiss MicroImaging GmbH, Germany) software.
Quantitative PCR analysis
Total RNA from differentiating mES and P19 EC cells
was harvested using RNeasy Mini Kit (Qiagen, Canada)
and analysed using real-time quantitative PCR (QPCR) as
described in refs (35,52). Brieﬂy, 1mg of RNA was
reverse-transcribed (RT) to synthesize cDNA using
Quantitect Reverse Transcription Kit (Qiagen, Canada).
To ensure successful removal of genomic DNA, no-RT
reaction was included. One-twentieth of RT reaction was
used as a template for QPCR ampliﬁcation using speciﬁc
primers listed in Table 1 and the FastStart SYBR
Green kit (Roche Applied Sciences, Canada) or Promega
GoTaq QPCR Master Mix (Promega, WI, USA). Data
were acquired using ABI7300 and ABI7500 QPCR
(Applied Biosystems, CA, USA) or Eppendorf Realplex2
(Eppendorf, Canada) instruments. Data were normalized
to b-actin, analysed as described in ref. (53), using P19 or
P19 control cell line Day 0 (monolayer cultures) as a cali-
brator, and expressed as percent maximum. Data
Table 1. Oligonucleotide sequences of primers utilized for real-time QPCR
Target Forward primer Reverse primer
b-actin AAATCGTGCGTGACATCAAA AAGGAAGGCTGGAAAAGAGC
BraT CTGGACTTCGTGACGGCTG TGACTTTGCTGAAAGACACAGC
GATA-4 AAAACGGAAGCCCAAGAACCT TGCTAGTGGCATTGCTGGAGT
Gli1 CCAAGCCAACTTTATGTCAGGG TCCTAAAGAAGGGCTCATGGTA
Gli/EnR GGAGAGTGTGGAGGCCAGTA CTGGGTTCCGGCTGTCTCT
Gli2 CAACGCCTACTCTCCCAGAC GAGCCTTGATGTACTGTACCAC
MEF2C TCTGTCTGGCTTCAACACTG TGGTGGTACGGTCTCTAGGA
MHC6 CAACAACCCATACGACTACGC ACATCAAAGGGCCACTATCAGTG
Nkx2-5 AAGGAACAGCGGTACCTGTC GCTGTCGCTTGCACTTGTAG
Oct-4 CAGCCAGACCACCATCTGTC GTCTCCGATTTGCATATCTCCTG
Ptch1 AAAGAACTGCGGCAAGTTTTTG CTTCTCCTATCTTCTGACGGGT
Tbx5 CTTTCGGGGCAGTGATGAC TTGGATGAGGTGGAGAGAGC
Nucleic Acids Research,2012, Vol.40, No. 8 3331represent mean±standard error of mean (SEM) from at
least two independent biological experiments and using
two clonal populations per cell line.
Northern blot analysis
RNA from differentiating P19 and P19[Nkx-MEF2C/
EnR] cells was harvested using the LiCl/Urea method
and analysed using northern blot procedure as described
previously (50). Brieﬂy, a total of 12mg of RNA for each
sample was separated by denaturing gel electrophoresis
and transferred to Hybond-N nylon membranes (GE
Life Sciences, Canada). The membranes were hybridized
with a-
32P deoxycytidine 50-triphosphate labelled
MEF2C/EnR and 18S cDNA fragments described previ-
ously (21). Results shown are representative of three
separate clones for each cell line.
Immunoblot analysis
Total protein extracts from differentiating mES and P19
EC cells and whole eyes of E16 Gli2
+/  heterozygous and
Gli2
 /  homozygous mice were harvested using radio-
immunoprecipitation assay buffer. In total, 10–20mgo f
protein was resolved using 4–12% gradient NUPAGE
gels (Invitrogen, Canada) according to manufacturer’s
protocol using 3-(N-morpholino)propanesulfonic acid/
sodium dodecyl sulfate running buffer. Resolved
proteins were transferred to polyvinylidene ﬂuoride or
nitrocellulose membranes, blocked in 5% milk and
reacted with Gli2 (54), calmodulin binding protein
(CBP) (Millipore, MA, USA), MEF2C (Santa Cruz,
sc-13266), a-tubulin (Sigma, DM1A) or b-actin speciﬁc
(Sigma, AC-74) antibodies. Signal was detected using
HRP-conjugated secondary anti-rabbit (Millipore, MA,
USA), anti-mouse (Cell Signalling, MA, USA) or
anti-goat (Santa Cruz, sc-2020) antibodies.
ChIP assays
A quantity of 50mg of chromatin from Day 5
differentiating P19[MEF2C] cells and 150mg of chromatin
from Day 4 differentiating P19[Gli2] cells was
immunoprecipitated using 2mg of MEF2C speciﬁc
(Santa Cruz, sc-13266), Gli2 speciﬁc (Santa Cruz, G-20)
or goat IgG non-speciﬁc antibodies (Invitrogen, Canada)
as described in ref. (51). Brieﬂy, cells were cross-linked
with 4% formaldehyde (Fisher Scientiﬁc, Canada) and
chromatin was sheared as described in ref. (51). Sheared
chromatin was incubated with Gli2, MEF2C or IgG
antibodies and the immune complexes were captured
using protein G sepharose beads as described previously
(51). Gli2, MEF2C or IgG-bound chromatin was
quantiﬁed as a percent chromatin input using QPCR
analysis as described above. To be considered a true asso-
ciation, each ChIP sample was examined for the enrich-
ment of a chromatin locus immunoprecipitated with a
speciﬁc antibody and compared with the same chromatin
locus immunoprecipitated with a non-speciﬁc IgG
(ANOVA with P<0.05), and compared with a negative
control locus, such as the Ascl1 (55) or Hdac4 locus
(ANOVA followed by post hoc Tukey honestly signiﬁcant
difference (HSD) test with P<0.05). Data represent
mean±SEM from three independent biological experi-
ments. Primers are listed in Table 2.
Co-immunoprecipitation assays
HEK-293 cells (ATCC, #CRL-1573) were seeded at 1
million cells per 100mm tissue-culture grade dish and
24h later co-transfected with a total amount of 3mgo f
Table 2. Oligonucleotide sequences of primers utilized for ChIP–QPCR experiments
Target gene Position of BS in
mm9 genome
Strand
Orien-
tation
Forward primer Reverse primer
Mef2c A Chr13: 83556197 - 83556209 + TGAAAAAGGAAATATCCCACTTAGA TTGCATGGGTTCACACCTAA
Mef2c B Chr13: 83589537 - 83589549 + AGTTGCCTGAGCCTGTTTTC TTTTTCGGCAATGATTTTCC
Mef2c C Chr13: 83657044 - 83657056 + TCTCCAGTTCCTGGGAAGAA CTTTCGGCTGGAGAGTCTTG
Mef2c D Chr13: 83663947 - 83663935 + ACACACGCACACTTCGTCTC GACCCACACAGAACCTTCAAA
Mef2c E Chr13: 83734849 - 83734861 + TTCCCATTTGGACCATTACC ACCCACGCACTGAGACTTTC
Mef2c F Chr13: 83772819 - 83772831 + AACCCCAATCTTCTGCCACT AAGCTTTCGCTAGACGTGGA
Mef2c G Chr13: 83800500 - 83800512 + GAGCCCCCTCTCTAATGTCC TGTGGGCAAGTGTCTTTCTG
Mef2c H Chr13: 83803968 - 83803980 + CGACCGACCTGCTTTACTTG AAGTGACATTTGGGGGTCCT
Mef2c I Chr13: 83879226 - 83879238 + CCTCCCCTCTTGTCAAAGTGT CCTAATTATTTCAGTTTGGGATGC
Ptch1 A Chr13: 63667821 - 63667833   TATTGCATGCGAGAGGGTTG GGAGGGCAGAAATTACTCAGC
Gli1 A Chr10: 126778677 - 126778689   GCACCCCCTCTCTAGCTTCTATC GGACCACCCGCGAGAAGCGCAAACT
Ascl1 A Chr10: 86936603 - 86936615   CCTAAGATCAATGGGCCAAA CCCACCCAACTGTCCTAGAG
Gli2 A Chr1: 120906302 - 120906324   AACAGGGTCTCTTCACATAGCC ATCTGCGGAGCACCTACTGT
Gli2 B Chr1: 120887621 - 120887643   GCATTTCTAAAGCTTGGTGGA CCGTGTTAAACATGACTAAAATGAT
Gli2 C Chr1: 120827230 - 120827246   TGAGTTATTGTTGGCGACTTCA AAACTGGTGTGCTGGCTAGG
Gli2 D Chr1: 120812203 - 120812225   CCCATTAACCACTGCTTTGC GCTATATTTTCCTATTCATGGCATAC
Gli2 E Chr1: 120799022 - 120799034   CTTCCCTGGGCCATTAAAGT TGCTAATACTCCCAGGCACA
Gli2 F Chr1: 120796554 - 120796566   TGCCCTAATTACACAAACAGCA CCTACTAATAACCTCCATGGATCA
Gata-4 A Chr14: 63864687 - 63864697 + AAGCGCTCTTTTCTCCTTCC GTGAGGGCTACAGGGAGTGA
MyoG A Chr1: 136186098 - 136186104 + ATTTGCCCTTCTGGGTTTCT GCTCAGCAGCACCTTAAACC
Hdac4 A Chr1: 93901621 - 93901643 + ATCTCCCACTGTTGGTCTGC GGTTTTCACTTTGTGGATTTGG
Chr: chromosome; BS: binding site.
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peptide) using Fugene (Roche, Canada). On completing
24h post-transfection, cells were washed twice with
ice-cold phosphate buffered saline and lysed with buffer
containing 50mM Tris–HCl, pH 7.4, 150mM NaCl,
1mM EDTA and 1% Triton X-100. Lysates were clariﬁed
by centrifugation for 15min at 13 krpm. In total, 0.5mg of
protein was subjected to FLAG immunoprecipitation (IP)
according to manufacturer’s protocol (Sigma-Aldrich,
MO, USA). Bound proteins were eluted by boiling the
beads in 1 SDS–PAGE loading buffer for 10min at
95 C. Transfection efﬁciency was monitored by
co-transfecting Green ﬂuorescent protein (GFP) and
analysing its autoﬂuorescence. All protein extraction and
incubation procedures were carried out at 4 C in the
presence of 1  protease inhibitor cocktail (Roche,
Canada) and 0.5mM phenylmethanesulphonylﬂuoride
(PMSF).
Eluted proteins from co-immunoprecipitation assays in
HEK-293 cells were resolved using 4–12% gradient
NUPAGE gels, transferred to polyvinylidene ﬂuoride
membranes and reacted with Gli2- or MEF2C-speciﬁc
antibodies as described above. Gli2 puriﬁcation efﬁciency
was quantiﬁed by band densitometry analysis using
ImageJ program (56).
Reporter assays
Gli2, MEF2C-Flag and GATA-4 expressing plasmids are
described elsewhere (25,47,57). Gli-responsive promoter is
described in ref. (58) and MEF2-responsive promoter is
from Affymetrix, CA, USA. The Nkx2-5 promoter,
comprising  3059 to+223nt relative to the Nkx2-5 tran-
scriptional start site, termed Nkx2-5-luc, is described in
Ref. (59).
P19 EC cells were plated at a density of 150000 cells/
35mm tissue-culture grade dish and transiently
co-transfected, as described above, 24h later with a total
amount of 3mg of DNA with or without Gli2,
MEF2C-Flag and the Nkx2-5 promoter, Gli-responsive
promoter or MEF2-responsive promoter driving
luciferase gene in the ratio 2:1 relative to luciferase re-
porters. Transfection efﬁciency was monitored by trans-
fecting Renilla as described previously (51). On completing
24h after transfection, cells were washed twice with
ice-cold phosphate buffered saline and lysed according
to Dual Luciferase Kit protocol (Promega, WI, USA).
Luciferase activity was assayed using 10–15ml of lysate
and LmaxII384 luminometer (Molecular Devices, USA).
To remove the background, the normalized activity of the
luciferase reporter plasmid alone was subtracted from its
activity in the presence of Gli2 and/or MEF2C and
GATA-4. The activity of the luciferase reporter in the
presence of protein expression plasmids was normalized
to the activity in the presence of Gli2 (arbitrarily set at
1). Synergy was calculated as described in ref. (60) accord-
ing to the following formula:
Synergy ¼
RLUsðMEF2C+Gli2Þ
RLUsðMEF2CÞ+RLUsðGli2Þ
,
where relative luciferase units (RLUs) represent luciferase
activity normalized to Renilla activity. P19 cells trans-
fected with GATA-4 and Nkx2-5-luc in ratio 2:1 served
as a positive control.
Bioinformatics analysis
Conserved Gli DNA binding sites and MEF2 DNA
binding sites in the Mef2c and Gli2 genes (±100kb)
were identiﬁed using Mulan (Multiple Sequence Local
Alignment and Visualization tool) as described previously
(61). The primers for identiﬁed binding sites were designed
using Primer 3 software (62) (for primer sequences, see
Table 2).
Putative genomic targets for both Gli and MEF2 tran-
scription factors were identiﬁed using SynoR (Genome
miner for synonymous regulation) as described previously
(63). The distance between neighbouring DNA binding
sites was set to (i) 4–100bp; (ii) 100–200bp and (iii)
200–300bp. The mouse genome (mm9) was used as a
base and was compared with the human genome (hg18).
Identiﬁed genes are listed in Supplementary Table S1.
Functional annotation analysis of the identiﬁed potential
targets was performed using DAVID (Database for
Annotation, Visualization, and Integrated Discovery)
software as described in Refs. (64,65). Selected gene
ontology biological processes are listed in Table 3.
Statistical analysis
ANOVA followed by post hoc Tukey HSD test was per-
formed using XLSTAT11 software (Addinsoft, NY, USA)
to determine statistical signiﬁcance between mean values
of two groups (*P<0.05; **P<0.01).
RESULTS
Gli2 and MEF2C are expressed during cardiomyogenesis
in mES and P19 EC cells
Differentiation of mES cells into cardiac muscle is sche-
matically depicted in Figure 1A, using a 7-day aggregation
protocol (25), where cardiac muscle forms as early as Days
8–9 (Figure 1A). Formation of cardiac muscle from mES
cells was conﬁrmed by indirect IF with an anti-MHC
antibody, MF20 (Figure 1B).
Changes in gene expression during cardiomyogenesis in
mES cells were examined for several markers (Figure 1C).
Downregulation of Oct-4, a marker of pluripotency in ES
cells (66), conﬁrmed that mES cells differentiated efﬁcient-
ly (Figure 1C, panel Oct-4). Notably, a slight upregulation
of Oct-4 was observed on Day 3, in agreement with a
previously reported role for Oct-4 in cardiac mesoderm
formation (67). The mesodermal marker BraT (68),
was also upregulated on Day 3 of mES differentiation
(Figure 1C, panel BraT). The highest expression of the
cardiac muscle precursor transcription factors Tbx5,
Nkx2-5 and GATA-4 (69–71) was detected during Days
6–9 of mES differentiation (Figure 1C, panels Tbx5,
Nkx2-5 and GATA-4). Finally, the highest expression of
the cardiac muscle marker MHC6 was detected on Day 9
of mES differentiation (Figure 1C, panel MHC6). During
Nucleic Acids Research,2012, Vol.40, No. 8 3333mES differentiation, MEF2C mRNA levels became highly
upregulated starting from Day 6 (Figure 1D, MEF2C
panel), whereas Gli2 mRNA levels were downregulated
starting from Day 3 (Figure 1D, Gli2 panel). There was
a trend in Gli1 mRNA downregulation on Days 3–6 of
differentiation (Figure 1D, panel Gli1). In contrast, Ptch1
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Figure 1. Gli2 and MEF2C are expressed during mES differentiation. (A) Schematic representation of cardiomyogenesis in D3 mES cells, as
described in ‘Materials and Methods’ section. (B–E) mES cells were differentiated and examined (B) for MHC expression using MF20 antibodies
on Day 9 of differentiation. Nuclei were stained with Hoechst, scale bar is 30mM; (C and D) by QPCR analysis for the indicated genes on Days 0, 3,
6 and 9 of differentiation, n=3. Error bars represent±SEM. Primers are listed in Table 1. (C) Values were compared with Day 0 values and
statistical signiﬁcance was determined using ANOVA (*P<0.05 and **P<0.01). (D) To determine statistical signiﬁcance between all days analysed,
ANOVA followed by post hoc Tukey HSD analysis was performed, *P<0.05 and **P<0.01; n.s.=not signiﬁcant.; (E) immunoblot analysis of
total protein extracts using MEF2C- and Gli2-speciﬁc antibodies at the time shown. Arrows designate Gli2 or MEF2C protein band(s), and asterisk
denotes non-speciﬁc binding of the Gli2 antibodies. a-Tubulin served as a loading control. Lanes were spliced out from the same autoradiogram as
designated by vertical lines. Gli2 band densities were measured from one representative experiment using ImageJ program (56), normalized to
a-tubulin and expressed as percent maximum; (F) immunoblot analysis of eye total protein extracts from E16 Gli2
+/  and Gli2
 /  mice using
Gli2-speciﬁc antibodies. Asterisk denotes non-speciﬁc binding of the antibodies. b-Actin served as a loading control.
Table 3. Selected gene ontology biological processes signiﬁcantly enriched among genes containing Gli and MEF2 conserved DNA
binding clusters in UTR, promoter, intron and coding sequence regions
Category Targets Fisher’s exact
P-value
Example genes
Cellular process 562 2.1E-17 E2F4, Glis1, CCNB2, Hdac9, RBBP4, TCF4
System development 189 6.1E-19 Tbx15, Fgf10, GSK3b, VEGFC, Sox6, Bmp1, Ar
Regulation of gene expression 172 6.4E-7 DNMT3A, POU4F2, Smarcc2, FOXA2, FOXD3,
HOXD10, Lhx2, Pbrm1
Cell differentiation 143 4.5E-13 ANGPT1, Bmp7, Fgf1, PAX2, Ptch1, Hhip, Twist1
Nervous system development 99 3.3E-15 BDNF, NRXN1, FOXP2, Gfra1, HOXB3
Embryonic development 68 3.5E-8 Notch2, Pdgfra, Pcgf2, HOXD10, ITGA8, Nr4a3
Neurogenesis 60 8.5E-9 Ntng1, NAV1, Lhx8, APP, Ctnna2
Skeletal system development 31 9.1E-5 Bmp5, Sox5, HOXB8, Tapt1
Chromatin organization 31 5.2E-4 MYST4, Phf15, ASH1L, ING2, Rnf2
Heart development 27 4.9E-5 MEF2C, FOXP1, TTN, Hdac5, ALPK3
Muscle organ development 17 1.5E-2 Dmd, Utrn, Rora, CACNG2
Vascular smooth muscle contraction 16 5.1E-4 Cacna1C, Cacna1D, BRAF, Prkca
For complete list of genes, see Supplementary Data. Altogether, 957 potential target genes were analysed as described in ‘Materials and
Methods’ section. The background set of genes used was the entire mouse genome.
3334 Nucleic Acids Research, 2012,Vol.40, No. 8mRNA was upregulated on Days 6–9 of mES differenti-
ation (Figure 1D, panel Ptch1). MEF2C and Gli2 protein
expression levels correlated with their mRNA expression
levels (Figure 1E). MEF2C protein expression was
induced after Day 3 of differentiation and Gli2 protein
expression was downregulated after Day 3, although its
expression persisted until Day 9 (Figure 1E).
To conﬁrm that the upper band on the Gli2
immunoblot did indeed correspond to Gli2 protein, we
analysed whole eye total protein extracts from Gli2
+/ 
heterozygous and Gli2
 /  homozygous mice. The only
band absent in the Gli2
 /  protein sample was the upper
band corresponding to  180kDa (Figure 1F). Thus, the
upper band represents Gli2 that correlates well with
previously published data (54,55) and with the theoretical
molecular weight of 165kDa for full-length mouse
Gli2 protein (database accession number Q0VGV1).
Therefore, both Gli2 and MEF2C proteins were ex-
pressed during mES cell cardiomyogenesis (summarized
in Table 4).
Since mES cells spontaneously differentiate into cell
types of all three germ layers upon removal of leukemia
inhibitory factor (77) and only a small proportion of cells
differentiate into cardiac muscle using a standard
embryoid body differentiation protocol, it is difﬁcult to
speciﬁcally correlate the expression proﬁle of MEF2C
and Gli2 with cardiac myogenic differentiation in a het-
erogeneous population of mES cells. P19 EC cells, in
contrast, mainly differentiate into mesoderm and
endothelial lineages upon addition of DMSO (27,30–34).
Moreover, P19 EC myogenic differentiation is very similar
to mES myogenic differentiation (25,35). For these
reasons, we compared the expression pattern of Gli2 and
MEF2C during mES differentiation with DMSO-induced
differentiation of P19 EC cells.
Cardiomyogenic differentiation of P19 EC cells is sche-
matically presented in Figure 2A. P19 EC cells treated
with DMSO successfully differentiated into cardiac
muscle on Day 6 as observed by indirect IF using
MHC-speciﬁc antibodies (Figure 2B). Gene expression
changes during cardiomyogenesis in P19 EC cells were
followed by QPCR analysis of myogenic markers
(Figure 2C). Downregulation of Oct-4 starting from Day
2 indicated the loss of pluripotency in EC cells (Figure 2C,
panel Oct-4). Induction of mesoderm is indicated by the
robust upregulation of BraT expression on Day 2 of dif-
ferentiation (Figure 2C, panel BraT). Induction of
cardiomyogenesis was conﬁrmed by elevated expression
of Nkx2-5, Tbx5 and GATA-4 during Days 5–6 of P19
EC differentiation (Figure 2C, panels Nkx2-5, Tbx5 and
GATA4). The robust expression of MHC6 on Day 6 of
differentiation conﬁrmed the formation of cardiac muscle
in EC cells (Figure 2C, panel MHC6). The expression of
MEF2C mRNA was signiﬁcantly elevated (P<0.01)
during Days 5–6 of DMSO-induced differentiation of
P19 EC cells (Figure 2D, panel MEF2C), and resembled
the temporal pattern observed in mES cells (Figure 1D,
panel MEF2C). There was a signiﬁcant increase (P<0.05)
in Gli2 mRNA expression during Days 5–6 of P19 EC
cardiomyogenesis (Figure 2D, panel Gli2). Gli1 mRNA
was upregulated on Day 4 of differentiation (Figure 2D,
panel Gli1). This data correlates with previous reports
showing upregulation of MEF2C and Gli2 mRNA expres-
sion during P19 EC DMSO-induced myogenesis using
northern blot analysis (35,41,42,47,51,78). Therefore,
MEF2C and Gli2 transcription factors are expressed
during mES and P19 EC cell cardiomyogenesis
(summarized in Table 4).
Gli2 regulates expression of MEF2C during
cardiomyogenesis in P19 EC cells
To study the ability of Gli2 to regulate the expression of
MEF2C during cardiomyogenesis in stem cells, we
examined P19 cells that stably overexpressed Gli2
(Figure 3). Stable overexpression of Gli2 was conﬁrmed
Table 4. Summary of gene expression changes in cell lines treated with or without DMSO
Cell line Treatment BraT Nkx2-5 GATA-4 Tbx5 MHC6 Gli2 MEF2C References
mES   +D3 +D6–9 +D6–9 +D6–9 +D9 +highest
on D0
+D6–9 Figure 1 (72,73)
P19 DMSO +D1–3 +D4–6 +D3–6 +D4–6 +D5–6 +D4–6 +D4–6 Figure 2 (27)
P19[Gli2] DMSO ±D2 + +D6 ++D6 ++D6 ++D6 ++ +D0–6 + +D4–9 Figure 3
P19[MEF2C-TAP] DMSO +D2 + +D6 ++D6 +D6 +D6 ++D4–5 + + +D0–6 Figure 3
P19[Gli/EnR] DMSO +D0–9 ±D4–6 ±D4–6 ±D4–6 ±D4–6 +D0–9 ±D4–6 Figure 4 (47,51)
P19[Nkx-MEF2C/EnR] DMSO +D2–6 ±
aD0–6  D0–6  D6  D6 ±D6 ±
aD0–6 Figure 5 (21)
P19[Nkx/EnR] DMSO + +D2–4 N.D.  D0–4, D6 N.D. N.D. N.D.  D6 (40)
P19[b-cat/EnR] DMSO ±D0-9 N.D. N.D. N.D. N.D.  D0-9 N.D. (74)
P19[Pax/EnR] DMSO + +D0–9 N.D. +D9 N.D. N.D. +D0–9 N.D. (75)
P19[Meox/EnR] DMSO +D0–9 +D6 +D6 N.D. N.D. ±D0–9 N.D. (47; Petropoulos and Skerjanc,
unpublished data)
P19[MyoD/EnR] DMSO N.D. N.D.  D9 N.D. N.D. ±D9  D9 (76)
P19[EnR] DMSO +D0–6 +D0–6 +D0–6 N.D. N.D. +D0–6 +D0–6 (40)
aThe expression of Nkx2-5 and MEF2C was elevated during Days 0–3, whereas it was downregulated during Days 4–6 of P19[Nkx-MEF2C/EnR]
differentiation as compared with P19 control cells [ref. (21) and Figure 7C].
Cell lines indicated on the right were aggregated under the conditions described in ‘Materials and Methods’ section and the induction of muscle
marker gene expression was monitored. (+ + +: high expression;+ +: elevated expression;+: normal expression; ±: downregulated expression,  : not
expressed or basal level of expression; N.D.: not determined). The timing of temporal gene expression in parental mES and P19 EC cells is shown.
For stable cell lines, the change in expression relative to the respective control cell lines and the day examined, were indicated (D=day).
Nucleic Acids Research,2012, Vol.40, No. 8 3335by immunoblot analysis using Gli2-speciﬁc antibodies
(Figure 3A). Antigenic analysis using MHC-speciﬁc
antibodies revealed an enhancement in the formation of
cardiomyocytes in Day 6 differentiated P19[Gli2] cultures
(Figure 3B and C). This was conﬁrmed by QPCR analysis,
which showed increased levels of Nkx2-5, Tbx5, GATA-4
and MHC6 mRNA in P19[Gli2] cells as compared
with P19[Control] cells (Figure 3D, panels Nkx2-5,
Tbx5, GATA-4 and MHC6) (summarized in Table 4).
Enhancement of cardiomyogenesis by Gli2 is consistent
with previous ﬁndings (3,41). Notably, overexpression of
Gli2 resulted in a slight downregulation (15±4%) of
BraT expression on Day 2 of differentiation (Figure 3D,
panel BraT). Furthermore, P19[Gli2] cells overexpressing
Gli2 protein showed a statistically signiﬁcant (P<0.05)
upregulation of MEF2C mRNA levels on Day 4 of
DMSO-induced differentiation (Figure 3D, panel
MEF2C), similar to results shown in the absence of
DMSO (41). There was also an 11- to 20-fold
upregulation of MEF2C protein levels in P19[Gli2] cells
on Days 6–9 of DMSO-induced differentiation as
compared to P19[Control] Day 4 (Figure 3A). The in-
creases in MEF2C protein expression on Days 6–9 in
P19 and P19[Gli2] cells (Figure 3A) correlate with the
pattern of MEF2C mRNA expression in P19 cells
(compare with Figure 2D), which peaks by Day 5. The
increase in MEF2C mRNA on Day 4 in P19[Gli2]
(Figure 3D) cells did not correlate with an obvious
increase in MEF2C protein on that day (Figure 3A),
possibly due to post-transcriptional regulation of the
MEF2C protein [reviewed in ref. (15)]. Overall,
overexpression of Gli2 upregulates MEF2C mRNA and
protein expression while enhancing cardiomyogenesis
(summarized in Table 4).
Since Gli transcription factors have overlapping func-
tions both in vivo and in vitro (79–82), the use of a
dominant negative fusion protein of Gli2 with the EnR
domain (Gli/EnR) would result in repression of all
Gli2-bound regulatory elements and the inability of Gli1
or Gli3 to rescue the phenotype. This approach has suc-
cessfully been used previously both in vitro and in vivo
(21,74,75,83,84). Furthermore, overexpression of
Engrailed does not interfere with cardiomyogenesis in
P19 EC cells (40). Stable overexpression of Gli/EnR
(Figure 4C, panel Gli/EnR) resulted in the formation of
fewer MHC-positive cardiomyocytes when compared with
P19 control cells (Figure 4A and B). Downregulation of
cardiac muscle cell differentiation was conﬁrmed by lower
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Figure 2. Gli2 and MEF2C are expressed during P19 EC DMSO-induced myogenesis. P19 EC cells were differentiated in the presence of 1% DMSO
as described in ‘Materials and Methods’ section. (A) Schematic representation of cardiomyogenesis in P19 EC cells. (B) P19 cells were examined for
MHC expression on Day 6 of differentiation using MHC-speciﬁc antibodies. Nuclei were stained with Hoechst dye. Scale bar is 30mM; (C and D)
QPCR analysis of the expression of the indicated genes at the times shown, n=3. Error bars represent±SEM. Primers are listed in Table 1; (C)
Day 2–6 values were compared with Day 0 values and statistical signiﬁcance was determined using ANOVA (*P<0.05 and **P<0.01); (D) to
determine statistical signiﬁcance between all days, ANOVA followed by post hoc Tukey HSD analysis was performed, *P<0.05 and **P<0.01;
n.s.=not signiﬁcant.
3336 Nucleic Acids Research, 2012,Vol.40, No. 8expression of MHC6 (Figure 4C, panel MHC6). The
mRNA levels of Tbx5 and GATA-4 were downregulated
since Day 4, whereas levels of Nkx2-5 were downregulated
most signiﬁcantly (P<0.05) on Day 6 of P19[Gli/EnR]
cellular differentiation (Figure 4C, panels Tbx5, Nkx2-5
and GATA-4). MEF2C mRNA was downregulated in
P19[Gli/EnR] cells on Days 5 and 6 of differentiation
(Figure 4C, panel MEF2C). The effect of MEF2C
downregulation is not due to global gene repression
by Gli/EnR fusion protein since Gli/EnR did not greatly
affect expression of mesodermal markers such as BraT in
DMSO-induced differentiation (47) (Table 4). P19[Gli/
EnR] cells did not lose pluripotency or the ability to dif-
ferentiate as they were shown to differentiate into glial and
neuronal cells in the presence of retinoic acid (55).
Therefore, Gli2, or genes bound by Gli2, is essential for
maintaining normal expression of MEF2C during cardio-
myogenesis in P19 EC cells (summarized in Table 4).
Gli2 associates with Mef2c gene elements during
cardiomyogenesis in P19 EC cells
In order to determine if Gli2 binds Mef2c gene elements
during cardiomyogenesis, we performed ChIP experi-
ments. In silico analysis of the Mef2c gene (±100kb)
revealed nine conserved theoretical Gli binding sites
(GBS) (Mef2c A–I, Figure 5A and B, summarized in
Table 2), suggesting that MEF2C could be a target of a
Gli transcription factor. Since the highest expression of
Gli2 protein and of MEF2C mRNA was detected on
Day 4 of P19[Gli2] cellular differentiation (Figure 3A
and D, respectively), we performed ChIP analysis of
Day 4 differentiating P19[Gli2] EC cells. After ChIP
with a Gli2 antibody, a statistically signiﬁcant enrichment
was observed of chromatin fragments, corresponding to
Mef2c sites B–I (Figure 5C). Mef2c site A appeared not to
be associated with Gli2 protein (Figure 5C), therefore
showing speciﬁcity of the ChIP assay. The Gli1 and
Ptch1 promoter regions were used as positive controls
and Ascl1 gene element was used as a negative control
(Figure 5C) based on previous observations (55,85,86).
From this result, we observe for the ﬁrst time that Gli2
is associated with Mef2c gene elements during
cardiomyogenesis in P19 EC cells.
MEF2C regulates expression of Gli2 during
cardiomyogenesis in P19 EC cells
To study the ability of MEF2C to regulate the expression
of Gli2 during cardiomyogenesis in vitro, we examined
P19 cells that stably overexpressed MEF2C-TAP
[tandem afﬁnity puriﬁcation tag (25)] (Figure 6). Stable
overexpression of MEF2C-TAP was conﬁrmed by
immunoblot analysis using CBP-speciﬁc antibodies that
recognized the TAP-tag of the MEF2C-TAP protein
(Figure 6A). Antigenic analysis using MHC-speciﬁc
antibodies revealed an enhancement in cardiac muscle for-
mation in P19[MEF2C-TAP] cells when compared with
their respective control cells (Figure 6B and C). This is
in agreement with previous ﬁndings, where MEF2C was
shown to induce cardiomyogenesis in the absence of
DMSO (45). We also observed signiﬁcantly (P<0.01)
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Figure 3. Gli2 upregulates MEF2C expression while enhancing
cardiomyogenesis in P19 EC cells. P19[Gli2] and P19[Control] cell
lines were differentiated in the presence of 1% DMSO. (A)
Immunoblot analyses of Gli2 and MEF2C protein expression in
differentiating P19[Control] and P19[Gli2] cells on Days 4, 6 and 9
using Gli2-speciﬁc or MEF2C-speciﬁc antibodies. Arrow designates
Gli2 protein band and asterisk denotes non-speciﬁc binding of the
Gli2 antibodies. b-Actin served as a loading control. Lanes were
spliced out from the same autoradiogram as designated by vertical
lines. MEF2C band densities from one representative experiment
were measured using ImageJ program (56), normalized to b-actin and
expressed as percent maximum; (B) Day 6 differentiated P19[Control]
and P19[Gli2] cultures were reacted with MHC-speciﬁc antibodies.
Nuclei were stained with Hoechst dye. Scale bar is 30mM; (C)
MHC-positive cardiomyocytes from (B) were counted in 10 random
ﬁelds and expressed as percent of the total number of nuclei, n=4.
In total, 13000 cells were counted; (D) QPCR analysis of the expression
of the genes indicated at the times shown in P19[Control] (black bars)
and P19[Gli2] (grey bars) cultures. Error bars represent ±SEM from
two biological replicas of two clonal populations (n=4). Statistical
signiﬁcance using an ANOVA test was determined between groups of
P19[Control] and P19[Gli2] samples analysed on the same day. For
MEF2C expression, ANOVA followed by post hoc Tukey HSD test
was performed to determine statistically signiﬁcant difference between
P19[Control] and P19[Gli2] samples on all days analysed, *P<0.05 and
**P<0.01. Primers are listed in Table 1.
Nucleic Acids Research,2012, Vol.40, No. 8 3337increased levels of Nkx2-5 and GATA-4, as well as a trend
of increased MHC6 transcripts in Day 6 differentiated
P19[MEF2C-TAP] cultures as compared with their
control cell line (Figure 6D, panels Nkx2-5, GATA-4
and MHC6). Notably, Tbx5 mRNA was not affected by
the expression of MEF2C-TAP (Figure 6D, panel Tbx5).
Also, expression of MEF2C-TAP did not affect BraT
transcript levels, suggesting that MEF2C-TAP affects
cardiomyogenesis after mesoderm induction (Figure 6D,
panel BraT). Furthermore, overexpression of
MEF2C-TAP resulted in the elevation of Gli2
mRNA expression on Day 4 of P19 EC differentiation
(Figure 3D, panel Gli2). We also observed an increase in
Gli2 protein levels up to 2.4-fold on Days 5 and 6 of
P19[MEF2C-TAP] differentiation as compared with
Day 5 of differentiation in P19[TAP] cells (Figure 6A).
Therefore, MEF2C upregulates Gli2 expression while
enhancing cardiomyogenesis in P19 EC cells (summarized
in Table 4).
To test if the expression of Gli2 can be regulated by a
dominant-negative MEF2C, we examined P19 EC cells
expressing MEF2C/EnR under the regulation of the
Nkx2-5 enhancer (Figure 7A). As reported previously
(21), P19[Nkx-MEF2C/EnR] cells failed to undergo
cardiomyogenesis as evidenced by the absence of MHC-
positive cardiac muscle cells (Figure 7B) and a severe
downregulation of Nkx2-5, Tbx5, GATA-4 and MHC6
mRNA (Figure 7C, panels Nkx2-5, GATA-4, Tbx5 and
MHC6). The phenotype of P19[Nkx-MEF2C/EnR]
cells is in accordance with previous reports showing
complete absence of cardiomyogenesis in vivo or in P19
EC cells (21). Expression of Nkx-MEF2C/EnR affected
cardiomyogenesis only, as differentiating P19[Nkx-
MEF2C/EnR] cells showed normal upregulation of
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Figure 4. Expression of Gli/EnR downregulates MEF2C expression while downregulating cardiomyogenesis in P19 EC cells. P19 and P19[Gli/EnR]
cell lines were differentiated in the presence of 1% DMSO. (A) Antigenic analysis of P19 and P19[Gli/EnR] using MHC-speciﬁc antibodies on Day 9
of differentiation. Nuclei were stained with Hoechst dye. Scale bar is 60mM; (B) MHC-positive cardiomyocytes from (A) were counted in 10 random
ﬁelds and expressed as percent of the total number of nuclei, n=4. In total, 16000 cells were counted; (C) QPCR analysis of the expression of the
genes indicated on Days 0 and 4–6 in P19 (black bars) and P19[Gli/EnR] (grey bars) cultures. Error bars represent ±SEM from two biological
replicas of two clonal populations (n=4). Statistical signiﬁcance using ANOVA test was determined between groups of P19 and P19[Gli/EnR]
samples analysed on the same day. For MEF2C expression, ANOVA followed by post hoc Tukey HSD test was performed to determine statistically
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3338 Nucleic Acids Research, 2012,Vol.40, No. 8Pax3 and Myf5 transcripts (data not shown), therefore
indicating normal skeletal myogenesis. Gli2 mRNA was
downregulated in P19[Nkx-MEF2C/EnR] cells on Day 6
of differentiation (Figure 7C, panel Gli2). The loss of Gli2
appears to be speciﬁc for a subset of dominant-negative
transcription factors, including Nkx-MEF2C/EnR
(Figure 7), which caused inhibition of cardiomyogenesis,
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Figure 6. MEF2C upregulates Gli2 expression while enhancing
cardiomyogenesis in P19 EC cells. P19[MEF2C-TAP] and P19[TAP]
cell lines were differentiated in the presence of 1% DMSO. (A)
Immunoblot analyses of MEF2C-TAP and Gli2 protein expression in
differentiating P19[MEF2C-TAP] and P19[TAP] cells on Days 5, 6 and
9 using Gli2-speciﬁc or CBP-speciﬁc antibodies. Arrow designates Gli2
protein band, and asterisk denotes non-speciﬁc binding of the Gli2
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Figure 5. Gli2 associates with Mef2c gene elements during
cardiomyogenesis in vitro.( A) Custom tracks of murine Mef2c, Gli1,
Ptch1 and Ascl1 genes using UCSC genome browser (http://genome.
ucsc.edu). Letters designate conserved Gli binding sites (GBS), their
genomic positions are listed in Table 2. Listed genes (±100kb) from
mouse and human genomes were searched for conserved theoretical
GBS as described in ref. (61); (B) comparison of mouse and human
sequences of Mef2c A–I sites from (A). The sequence of the Gli2
binding site is marked in bold. (C) ChIP analysis of Gli2-bound
Mef2c, Gli1, Ptch1 and Ascl1 genes on Day 4 of P19[Gli2] cellular
differentiation in the presence of 1% DMSO. Black bars designate
genomic regions immunoprecipitated with Gli2-speciﬁc antibodies,
and grey bars designate genomic regions precipitated with IgG-non-
speciﬁc antibodies. Gli1 and Ptch1 promoters served as positive
controls, Ascl1 gene element served as a negative control. Percent chro-
matin input was calculated using QPCR analysis and primers listed in
Table 2. Error bars represent±SEM from three biological replicas
(n=3). Statistical signiﬁcance was determined as described in
‘Materials and Methods’ section. *P<0.05, **P<0.01.
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(continued)and MyoD/EnR (76), Meox/EnR (47), and ß-catenin/
EnR (74), which caused inhibition of skeletal myogenesis
(Table 4). In contrast, Gli2 levels were not downregulated
in P19 cells expressing Pax/EnR (75) that resulted in the
loss of skeletal myogenesis (Table 4). Thus, MEF2C, or
genes bound by MEF2C, is essential for maintaining
normal Gli2 expression during cardiomyogenesis in P19
EC cells (summarized in Table 4).
MEF2C associates with Gli2 gene elements during
cardiomyogenesis in stem cells
To test if MEF2C can bind Gli2 gene elements, in silico
analysis of the Gli2 gene (±100kb) revealed six con-
served theoretical MEF2 binding sites (MBS) (Gli2 A–F,
Figure 8A and B, summarized in Table 2) suggesting that
Gli2 could be a target of MEF2. ChIP analysis of Day 5
differentiating P19[MEF2C] cells revealed statistically sig-
niﬁcant enrichment, with a MEF2C antibody, of chroma-
tin fragments corresponding to Gli2 A–D and F sites, but
not to Gli2 E site (Figure 8C). The Hdac4 intron region,
which is located on the same chromosome as the Gli2 gene
(summarized in Table 2), was not enriched in the ChIP
assay with MEF2C antibodies (Figure 8C), therefore
serving as a negative control and demonstrating the spe-
ciﬁcity of ChIP analysis using MEF2C-speciﬁc antibodies.
The Gata-4 and MyoG promoter regions were used as
positive controls (Figure 8C). Therefore, MEF2C is
associated with Gli2 gene elements during cardio-
myogenesis in P19 EC cells.
Gli2 and MEF2C factors form a protein complex
that can function synergistically
Based on the ﬁnding that Gli2 and MEF2C are
co-expressed during later stages of cardiomyogenesis in
mES and during P19 EC cardiomyogenesis (Figures 1
and 2, respectively) and they regulate each other’s expres-
sion, as well as have similar abilities to regulate
cardiomyogenesis in P19 EC cells (Figures 3 and 6), we
hypothesized that these transcription factors may form a
protein complex to synergistically regulate the expression
of cardiomyogenesis-related genes.
To test this hypothesis, we ﬁrst explored the ability
of Gli2 and MEF2C to synergize in luciferase reporter
assays. To this end, we took advantage of an endogenous
Nkx2-5 promoter ( 3059 to +223nt relative to Nkx2-5
transcriptional start site), which was shown to drive
gene expression in the cardiac crescent at E7.25, as well
as outﬂow tract and right ventricle at E10.5, and require
combinatorial function of multiple regulatory factors (59).
This Nkx2-5 promoter contained 3XGli, 3XMEF2,
6XGATA-4, 3XNkx and 1XTbx5 binding sites and was
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Figure 7. Expression of Nkx-MEF2C/EnR downregulates Gli2 expres-
sion while inhibiting cardiomyogenesis in P19 EC cells. P19[Control]
and P19[Nkx-MEF2C/EnR] cell lines were differentiated in the
presence of 1% DMSO. (A) Northern blot analysis of the expression
of MEF2C/EnR mRNA in P19 and P19[Nkx-MEF2C/EnR] cells on
Days 0 and 2–6. Here, 18s served as a loading control. Lanes were
spliced out from the same autoradiogram as designated by vertical
lines. (B) Antigenic analysis of P19 and P19[Nkx-MEF2C/EnR] using
MHC-speciﬁc antibodies on Day 6 of DMSO-induced differentiation.
Nuclei were stained with Hoechst dye. Scale bar is 60mM. (C) QPCR
analysis of the expression of Nkx2-5, GATA-4, Tbx5, MHC6 and Gli2
mRNA in differentiated P19[Control] and P19[Nkx-MEF2C/EnR] cells
on Days 0 and 6. Error bars represent ±SEM from two biological
replicas of two clonal populations (n=4). Statistical signiﬁcance
using ANOVA test was determined between groups of P19 and
P19[Nkx-MEF2C/EnR] samples analysed on the same day. For Gli2
expression, ANOVA followed by post hoc Tukey HSD test was per-
formed to determine statistically signiﬁcant differences between P19 and
P19[Nkx-MEF2C/EnR] samples on all days analysed. *P<0.05,
**P<0.01. Primers are listed in Table 1.
Figure 6. Continued
from two biological replicas of two clonal populations (n=4).
Statistical signiﬁcance using ANOVA test was determined between
groups of P19[TAP] and P19[MEF2C-TAP] samples analysed on the
same day. For Gli2 expression, ANOVA followed by post hoc Tukey
HSD test was performed to determine statistically signiﬁcant differences
between P19[TAP] and P19[MEF2C-TAP] samples on all days
analysed. *P<0.05 and **P<0.01. Primers are listed in Table 1.
3340 Nucleic Acids Research, 2012,Vol.40, No. 8fused to the luciferase gene (Nkx2-5-luc) (59) (Figure 9A).
When Gli2 and MEF2C were co-transfected together, they
synergistically activated the Nkx2-5 promoter up to
6±2-fold as compared with the theoretical additive
value of 3±0.3-fold change (Figure 9B, dashed line).
The activation of the Nkx2-5 promoter by Gli2
and MEF2C together was similar to that of GATA-4
alone (Figure 9B). When Gli2 and MEF2C were
co-transfected with luciferase reporters containing either
5xGli or 5xMEF2 binding sites alone, no synergy or
additive effect was observed (data not shown).
Therefore, Gli2 and MEF2C synergistically activate the
Nkx2-5 promoter.
To test if Gli2 and MEF2C formed a protein complex,
we co-transfected Gli2 and MEF2C-Flag or Flag-vector
into HEK-293 cells. Gli2 co-immunoprecipitated
with MEF2C-Flag, but not with the Flag-tag alone
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Figure 9. Gli2 and MEF2C form a protein complex and synergize on
the Nkx2-5 promoter. (A) Schematic representation of Nkx2-5-luc
reporter construct. Circles designate Gli (white), MEF2 (grey), Nkx
(green), GATA-4 (red) and Tbx5 (black) binding sites; +1 designates
transcriptional start site (TSS);  3059 designates the beginning of the
Nkx2-5 promoter relative to (TSS); (B) Gli2 and MEF2C were trans-
fected alone or together with or without Nkx2-5-luc in P19 cells. Cells
transfected with GATA-4 served as a positive control. Error bars rep-
resent ±SEM from 10 biological replicas (n=10). *P<0.05. The
dashed line represents the value at which Gli2 and MEF2C function
additively. Transfection efﬁciency was monitored by assaying activity of
co-transfected Renilla luciferase. Synergy and statistical signiﬁcance
was calculated as described in ‘Materials and Methods’ section. The
average activation of Nkx2-5-luc by Gli2 was 2.3±0.4 (data not
shown) and was normalized to 1; (C) Gli2 was co-immunoprecipitated
with MEF2C-Flag but not with Flag-vector when transfected in
HEK-293 cells. Transfection efﬁciency was monitored by assaying
autoﬂuorescence of co-transfected GFP. Arrow designates Gli2
protein band, and asterisk denotes non-speciﬁc binding of the Gli2
antibodies. Lanes were spliced out from the same autoradiogram
as designated by vertical lines. (D) Quantiﬁcation of Gli2 band
density from elution fractions in (C) using ImageJ program.
Error bars represent±SEM from three biological replicas (n=3),
*P<0.05.
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Figure 8. MEF2C associates with Gli2 gene elements during
cardiomyogenesis in vitro. P19[TAP] and P19[MEF2C-TAP] cell lines
were differentiated in the presence of 1% DMSO. (A) Custom tracks of
murine Gli2, Gata-4, MyoG and Hdac4 genes using UCSC genome
browser (http://genome.ucsc.edu). Letters designate conserved MEF2
binding sites (MBS), their genomic positions are listed in Table 2.
Listed genes (±100kb) from mouse and human genomes were
searched for conserved theoretical MBS as described in ref. (61);
(B) comparison of mouse and human sequences of Gli2 A–F sites
from (A). The sequence of the MBS is marked in bold. (C) ChIP
analysis of MEF2C-bound Gli2, Gata-4, MyoG and Hdac4 genes
during P19[MEF2C] cellular differentiation. Black bars designate
genomic regions immunoprecipitated with MEF2C-speciﬁc antibodies,
and grey bars designate genomic regions precipitated with IgG-non-
speciﬁc antibodies. Gata-4 and MyoG promoters served as positive
controls, Hdac4 gene element served as a negative control. Percent
chromatin input was calculated using QPCR analysis and primers are
listed in Table 2. Error bars represent ±SEM from three biological
replicas (n=3). Statistical signiﬁcance was determined as described in
‘Materials and Methods’ section. *P<0.05, **P<0.01.
Nucleic Acids Research,2012, Vol.40, No. 8 3341(Figure 9C). Analysis of autoﬂuorescence of
co-transfected GFP was performed to ensure that all
samples were transfected with equal efﬁciency.
Quantitative analysis of bands corresponding to Gli2
protein revealed a 4±1-fold higher amount of Gli2
co-immunoprecipitated with MEF2C-Flag when
compared with co-IP with Flag-vector (Figure 9D).
Therefore, Gli2 and MEF2C proteins physically associate
and synergistically activate transcription.
DISCUSSION
We have shown that Gli2 and MEF2C are associated with
each other’s gene elements and are able to regulate each
other’s expression during cardiomyogenesis in P19 EC
cells. Further, Gli2 and MEF2C form a protein complex
capable of synergistically activating gene promoters that
participate in cardiomyogenesis. Thus, we propose a
model similar to that for MEF2 and myogenic regulatory
factors (MRFs) [reviewed in ref. (15)], where Gli2 and
MEF2C transcription factors induce and maintain each
other’s expression, as well as form a protein complex
that synergizes on promoters containing both Gli and
MEF2 binding elements during cardiomyogenesis
(Figure 10). It is likely that other transcription factors
participate in the Gli2–MEF2C protein complex,
designated as ‘?’.
Our results obtained in vitro provide added mechanistic
insight into the roles of Gli2 and MEF2C in
cardiomyogenesis. Whereas only cardiac outﬂow tract
anomalies were detected in the developing hearts of
Gli2
 / Gli3
+/  mice (6,14), MEF2C
 /  mice had heart
looping defects along with gross abnormalities in the
right ventricle, as well as in the outﬂow tract (19,20).
This suggests that Gli2 and MEF2C may function co-
operatively during cardiac outﬂow formation. Our
studies are consistent with an overlapping pattern of
defects that could be explained by Gli2 and MEF2C
having both shared and distinct subsets of targets, likely
dependent upon the unique protein complexes formed in
each case.
The results from this study suggest that both Gli2 and
MEF2C may be active at the cardiac muscle progenitor
stage. This is supported by the embryonic expression
patterns of MEF2C (starting from E7.5) (16,17) and
Gli1 (E7.0–8.0) (3,10), which are both expressed after
mesodermal markers BraT (E6.5) and MESP1 (E6.5),
and concomitantly with the cardiac progenitor marker
Nkx2-5 (E7.0) [reviewed in ref. (87)]. Although the expres-
sion of Gli2 resulted in downregulated expression of
BraT, the decrease was minimal (15±4%) in comparison
with the upregulation of expression of other factors
(Figure 3D). Furthermore, overexpression of MEF2C,
Nkx-MEF2C/EnR and Gli/EnR did not affect the expres-
sion of BraT in P19 EC cellular differentiation [refs
(21,45,47) and Figure 6D], while affecting the expression
of cardiac muscle progenitor markers Nkx2-5 and
GATA-4 [(21,41,45) and Figures 4C, 6D and 7C].
The temporal patterns of MEF2C and Gli2 expression
we identiﬁed in both P19 EC and mES cells are consistent
with previous reports. MEF2C mRNA is upregulated
during cardiomyogenesis in mES cells by Day 6, after ex-
pression of mesodermal markers BraT and Mesp1/2 (72)
and in P19 EC cells from Days 6–7 (27), similar to our
ﬁndings (Figures 1 and 2). Much less information is avail-
able about the expression of Gli transcription factors
during ES myogenesis. It is known that Shh signalling
members are expressed in undifferentiated hES cells (88),
as well as in cardiomyocytes derived from P19 EC (41,42),
P19CL6 (43) and mES cells stably expressing
neomycin-resistance gene under the regulation of cardiac
a-MHC promoter (23). A further complication is that Gli2
is expressed in numerous lineages, including brain, bone,
cartilage, muscle, lung and pancreas [reviewed in ref. (89)].
In addition, Gli2 might be involved in maintaining stem
cell pluripotency in ES cells as it was shown to directly
regulate expression of the pluripotency markers Sox2 (90)
and Nanog (91). Thus, it is possible that a high level of
Gli2 expression is necessary to maintain the pluripotent
state of ES cells, and lower level of Gli2 expression is
sufﬁcient to support mES differentiation. This phenom-
enon has been shown previously for Oct-4 and Sox2,
which play roles in maintaining pluripotency (66,92), as
well as in directing early stages of ES cell differentiation
(67,93). Finally, the primary effect of the Hedgehog (Hh)
signalling is the activation of Gli2 protein function, as
opposed to the upregulation of Gli2 mRNA or protein
expression (94,95). The elevated expression of Ptch1,
marker of active Hh signalling (96), during Days 6–9 of
mES differentiation (Figure 1D), suggests that the Hh
signalling pathway is active when MEF2C is expressed
in differentiating mES cells (Figure 1D).
In comparison with mES cells (77,97), DMSO-treated
P19 EC cells differentiate into only a limited number
of mesodermal and endodermal lineages (27,30–34). In
this system, Gli2 expression was upregulated during
cardiomyogenesis from Days 5–6 (Figure 2D), in agree-
ment with previous studies (41,42). Furthermore, Gli2 was
signiﬁcantly upregulated in the same temporal pattern as
MEF2C (Figure 2D). In summary, P19 EC cells provide a
good model system for examining the functional inter-
action between Gli2 and MEF2C.
It was previously demonstrated that Gli2 induced the
expression of MEF2C and cardiomyogenesis in P19 EC
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Figure 10. Gli2 and MEF2C interact during cardiomyogenesis in vitro.
We propose a model in which Gli2 and MEF2C induce each other’s
expression and bind each other’s gene elements (designated by thick
arrow), as well as form a protein complex on gene promoters capable
of synergistically activating their expression. Other protein(s)
participating in the Gli2/MEF2C protein complex are designated by ‘?’.
3342 Nucleic Acids Research, 2012,Vol.40, No. 8cells in the absence of DMSO (41). Recently, it was shown
that the activation of the Shh signalling pathway
upregulated MEF2C mRNA transcript levels in the
second heart ﬁeld in vivo after chick embryos were
treated with Shh signalling pathway activator, SAG
agonist, at HH14 (98). Drosophila embryos expressing
mutant loss-of-function MEF2 protein showed
downregulated expression of Ci (Cubitus Interruptus, a
single Drosophila homolog of vertebrate Gli transcription
factors) (99). Our results support and extend previous
results by showing that Gli2 and MEF2C can upregulate
each other’s expression while enhancing DMSO-induced
cardiomyogenesis in P19 EC cells, suggesting the possibil-
ity that they function in a regulatory loop.
Gli2 and MEF2C enhanced each other’s mRNA expres-
sion on Day 4 of differentiation, and not in undifferenti-
ated cells (Day 0). It was previously shown that MyoD, a
master-regulator of skeletal myogenesis capable of con-
verting ﬁbroblasts into skeletal myocytes (100), induced
skeletal myogenesis in P19 EC cells only upon cellular
aggregation (101,102). Indeed, all of the muscle transcrip-
tion factors studied to date in P19 EC cells required
cellular aggregation to be functional (21,40,45–
47,50,52,74–76,78,101–103,114). It is therefore not
surprising that the expression levels of Gli2 and MEF2C
were not affected in undifferentiated (Day 0) P19 stable
cell lines.
The expression of dominant-negative Gli2 resulted in
downregulation of MEF2C expression and cardio-
myogenesis. To our knowledge, this is the ﬁrst indication
that the expression of Gli/EnR results in impaired
cardiomyogenesis in P19 EC cells. Previous reports
showed that Shh signalling is not essential for cardio-
myogenesis during embryogenesis (3,4) or in P19 EC
cells (42), although a reduction or delay of cardio-
myogenesis was observed. However, treatment of a
cardiac lineage-restricted subline of P19 cells, P19CL6
cells, with the Shh signalling inhibitor cyclopamine
blocked their differentiation into beating cardiac
myocytes (43). The difference in the latter results may be
due to a lack of compensatory signalling molecules,
derived from other lineages, implicated in activating Gli
factors, such as TGFb (104), Fgf (105) and Wnt (106).
Finally, Zic factors have also been shown to bind
genomic Gli binding sites and to modulate the transcrip-
tional activity of Gli transcription factors (107). Our use
of a dominant-negative approach would override compen-
satory activating signals (47,55), showing a role for Gli2
function during cardiomyogenesis.
While ubiquitously expressed Gli2 and MEF2C each
enhanced cardiomyogenesis (Figures 3 and 6), and ubiqui-
tously expressed Gli/EnR impaired cardiomyogenesis
(Figure 4), surprisingly pgk-driven MEF/EnR enhanced
cardiomyogenesis (46) and skeletal myogenesis
(Karamboulas and Skerjanc, unpublished data). This is
likely due to the dual nature of MEF2 factors, which
have the ability to recruit HDAC4/5 to genes, inhibiting
transcription (108), as well as recruiting histone
acetyltransferases, activating transcription (108). A repres-
sive role for Gli2 in regulating entry into various lineages
was not observed, since the expression of Gli/EnR under
the pgk promoter resulted in abolished skeletal myogenesis
(47) and attenuated levels of neurogenesis and gliogenesis
(55) at a speciﬁc stage of each respective differentiation
program (47,55). Therefore, expression of Gli2/EnR
under a general promoter such as pgk, impaired the for-
mation of different stem cell differentiation pathways,
including cardiomyogenesis, at speciﬁc stages.
While overexpression of MEF2C-TAP upregulated
transcript levels of Gli2, Nkx2-5 and GATA-4, it did
not affect Tbx5 mRNA expression. This correlates with
previous studies, where knockdown of MEF2C using
morpholinos disrupted zebraﬁsh heart tube looping, but
did not affect Tbx5 expression (109). It is possible that
other MEF2 family proteins were able to rescue the ex-
pression of Tbx5 in zebraﬁsh (109). Genetic redundancy of
MEF2C family members is supported by our ﬁnding that
the expression of Tbx5, Gli2 and cardiac muscle progeni-
tor markers was drastically reduced in the presence of
dominant-negative Nkx-MEF2C/EnR in vitro, and the
loss of heart formation in vivo (21). It is likely that the
Nkx2-5 enhancer driving the expression of MEF2C/EnR
can be regulated by Gli2 and the previously described
regulatory loop between MEF2C, GATA-4 and Nkx2-5
(21,40,45,78). Thus, as Nkx2-5 is expressed during forma-
tion of cardiac muscle progenitors, the overexpression of
Nkx-MEF2C/EnR will inhibit the function of endogenous
MEF2C and Gli2, as well as other cardiogenic factors,
resulting in the loss of cardiomyogenesis. This is sup-
ported by the fact that both endogenous Gli2 and
MEF2C were downregulated, but not abolished, by Day
6 in P19[Nkx-MEF2C/EnR] cells, whereas the expression
of Nkx-MEF2C/EnR was reduced [ref. (21) and Figure 7].
We report for the ﬁrst time that Gli2 and MEF2C as-
sociate with each other’s gene elements. Although existing
literature supports identiﬁcation of Gli2 as a target of
MEF2C by demonstrating that the Drosophila MEF2
protein directly bound gene elements of Ci (a Drosophila
homolog of vertebrate Gli transcription factors) (99),
MEF2C was not previously reported to be a target of
Gli3 in murine developing limb in a genome-wide
ChIP-on-chip analysis (110). It is possible that MEF2C
is a target of the Gli transcription factors at an earlier
time-point than the time-point analysed in the study
(E11.5) (110). Members of the Shh signalling pathway
are expressed starting from E8.0 in murine paraxial
mesoderm (81) and MEF2C is the ﬁrst MEF2 family
factor to be expressed in somites starting from E8.5–9.0
(16). Finally, it is possible that MEF2C is a target of Gli2
and not Gli3, during cardiomyogenesis.
Notably, the majority of the Gli2-bound sites are
located in the intron regions of the Mef2c gene. It was
previously shown that there are multiple promoter and
enhancer regulatory elements within the Mef2c gene
introns (17,111,112). Of those known regulatory elements
in the Mef2c gene, the Mef2c D site, which was bound by
Gli2 in this study, is located  +500bp relative to the
30-end of the reported cardiac promoter (17). Thus, it is
possible that other Mef2c gene elements bound by Gli2 are
located within novel regulatory regions, however, their
identiﬁcation is outside the scope of this study.
Nucleic Acids Research,2012, Vol.40, No. 8 3343Much like the Mef2c gene sites bound by the Gli2
protein, Gli2 sites bound by the MEF2C protein are
located in the intron regions of the Gli2 gene. Although
regulatory elements in the Gli2 gene have not yet been
reported, it is possible that its introns contain novel
uncharacterized regulatory regions. For example, the
Gli2 B site that was bound by MEF2C in this study, is
part of the predicted genomic enhancer, which is well
conserved between human, mouse, chicken, frog and
fugu genomes [ref. (113), element hs1790]. Although this
region was not found to have any enhancer activity at
E11.5 when transfected into mouse embryos in a
reporter cassette driving b-gal expression [ref. (113),
element hs1790], it is possible that it can act as an
enhancer at an earlier or later time point in development.
Both Gli2 and MEF2C are capable of enhancing the
development of cardiac muscle through upregulation of
the Nkx2-5, GATA-4 and BMP-4 regulatory loop [this
study and refs (41,45)], skeletal muscle via upregulation
of MRFs (47,48) and neurons through enhancement of
Ascl1/Mash1 expression (55,114) in pluripotent P19 EC
cells. The ability of Gli2 and MEF2C to regulate a
similar subset of differentiation pathways in pluripotent
P19 EC cells, led us to hypothesize that Gli2 and
MEF2C could function together. We showed that Gli2
and MEF2C form a protein complex that functions syn-
ergistically on the Nkx2-5 promoter. MEF2 proteins are
known to form synergistic protein complexes with cardiac
muscle factors such as Hand1 (115) and GATA-4 (116).
More recently, MEF2C, together with GATA-4 and Tbx5,
was shown to convert mouse ﬁbroblasts into cardiac
myocytes (117). Furthermore, our ﬁndings are consistent
with Pitx2, which is a homeodomain transcription factor
involved in heart development, and MEF2 protein
complex studies, where both MEF2 and Pitx2 DNA
binding sites were necessary for the synergistic action of
the protein complex (118).
In silico analysis of the mouse genome identiﬁed 957
genes containing both Gli and MEF2 conserved DNA
binding clusters (Supplementary Table S1). Functional an-
notation analysis of these potential targets revealed a
number of categories enriched among Gli and MEF
clusters containing genes, such as cell differentiation, regu-
lation of gene expression, chromatin organization, as well
as development of nervous system, heart, the skeletal
system and muscle organ (Table 3). While Nkx2-5 was
not identiﬁed as a target gene for Gli2 and MEF2C,
probably due to the presence of non-conserved Gli and
MEF2 binding elements and/or due to stringent restric-
tions used in the screening process, MEF2C was identiﬁed
as one of the potential target genes for both Gli and
MEF2 transcription factors (Supplementary Table S1
and Table 3). The identiﬁcation of numerous potential
Gli and MEF2 targets regulating various lineages
implies that the Gli2/MEF2C interactions identiﬁed here
may be applicable to other lineages and require further
study.
In summary, we propose a novel mechanistic model, in
which Gli2 and MEF2C transcription factors induce and
maintain each other’s expression, as well as form a protein
complex capable of synergizing on gene promoters
containing both Gli and MEF2 binding elements during
cardiomyogenesis in vitro (Figure 10). This is the ﬁrst
evidence that the Shh signalling pathway is directly
linked to the function of MEF2C protein. Our ﬁndings
are similar to the MEF2 and MRF interaction model
[reviewed in ref. (15)]. The Gli2/MEF2C protein
complex may function during the induction of several
lineages, including cardiac and skeletal muscle, as well as
neurons. This is supported by the identiﬁcation of
numerous putative targets for both Gli2 and MEF2C,
which are enriched in neurogenesis, as well as skeletal
muscle and heart developmental processes (Table 3).
Understanding the complex network of transcription
factors that regulates lineage determination during stem
cell differentiation is important for potential future cell
therapies.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Table 1.
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